Gene and Cell Therapies Targeting CNS Disorders Market Research 2025-2035 Technological Advancements in Precision Delivery Drive Growth, High Costs Challenging Accessibility
| CRSP Stock | USD 55.59 4.00 6.71% |
Slightly above 62% of Crispr Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Crispr Therapeutics AG stock suggests that many investors are alarmed at this time. Crispr Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Crispr Therapeutics AG. Many technical investors use Crispr Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
The gene and cell therapies market targeting central nervous system disorders is rapidly advancing, driven by increasing incidences of conditions...
Read at globenewswire.com
 |
Crispr Therapeutics Fundamental Analysis
We analyze Crispr Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crispr Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crispr Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Crispr Therapeutics is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Crispr Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Crispr Therapeutics stock to make a market-neutral strategy. Peer analysis of Crispr Therapeutics could also be used in its relative valuation, which is a method of valuing Crispr Therapeutics by comparing valuation metrics with similar companies.
Peers
Crispr Therapeutics Related Equities
| NTLA | Intellia Therapeutics | 5.48 | ||||
| DNA | Ginkgo Bioworks | 5.00 | ||||
| PACB | Pacific Biosciences | 2.16 | ||||
| EDIT | Editas Medicine | 1.56 | ||||
| TDOC | Teladoc | 0.14 | ||||
| BEAM | Beam Therapeutics | 2.20 | ||||
| VRTX | Vertex Pharmaceuticals | 20.60 |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.